Dual Immune Checkpoint Inhibitors in Advanced Cutaneous Melanoma

Conference Correspondent —December 15, 2021
Sanjiv S. Agarwala, MD
Professor
Temple University School of Medicine
Philadelphia, PA

Dr Sanjiv Agarwala reviews data for first-line immunotherapy with nivolumab plus relatlimab demonstrating significantly improved progression-free survival over monotherapy, and a high pathologic complete response rate with this combination in the neoadjuvant setting, in patients with advanced melanoma. He also reviews data from the CheckMate-067 study showing durable 6.5-year overall survival with first-line nivolumab plus ipilimumab in patients with advanced melanoma.

Related Articles
Phase 2 Study of Nivolumab plus Ipilimumab in Metastatic Uveal Melanoma
Conference Correspondent
Nivolumab plus ipilimumab demonstrates deep and sustained confirmed responses for patients with metastatic uveal melanoma.
Phase 2 Trial of Nivolumab plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: Spanish Multidisciplinary Melanoma Group (GEM-1402)
Conference Correspondent
Nivolumab plus ipilimumab demonstrated improvement in overall survival for patients with metastatic uveal melanoma.
Benefits of Dual I-O Therapy in Metastatic Uveal Melanoma
Sanjiv S. Agarwala, MD
|
Conference Correspondent
The combination of nivolumab and ipilimumab offers deep and sustained responses and improved overall survival in malignant uveal melanoma.
Last modified: December 15, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code